Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$83.80 USD

83.80
1,221,297

+0.47 (0.56%)

Updated May 2, 2024 04:00 PM ET

After-Market: $83.76 -0.04 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BMRN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

BioMarin Pharmaceutical Inc. [BMRN]

Reports for Purchase

Showing records 781 - 800 ( 812 total )

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 781

02/18/2011

Company Report

Pages: 8

Q4 Financials: Annual Growth Intact Despite Quarterly Choppiness

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 782

02/16/2011

Company Report

Pages: 8

Q4 Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 783

02/09/2011

Company Report

Pages: 7

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 784

02/04/2011

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of February 6

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 785

01/25/2011

Company Report

Pages: 6

Next Wave of Pipeline Products Enter Clinic

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 786

01/14/2011

Industry Report

Pages: 5

LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of January 16

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 787

12/17/2010

Daily Note

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: JAMES S

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 788

12/15/2010

Industry Report

Pages: 19

2011 Major Value Drivers in Emerging Pharmaceuticals.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 789

12/10/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: JAMES S

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 790

12/03/2010

Daily Note

Pages: 4

BMN 673 Approved For Clinical Trial Testing In The UK

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 791

11/26/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: JAMES S

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 792

11/12/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 793

11/09/2010

Company Report

Pages: 7

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 794

10/30/2010

Company Report

Pages: 8

Strong 3Q10 Overall Performance

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 795

10/29/2010

Company Report

Pages: 8

Q3 Financials: Revenues A Bit Light. 2010 Guidance Tightened. We See 2011 As A Potential Inflection With Multiple Catalysts

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 796

10/25/2010

Company Report

Pages: 11

Q3 Preview: We See An In-Line Q3 With A Substantial One-Time Tax Benefit

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 797

10/08/2010

Company Report

Pages: 7

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 798

09/13/2010

Company Report

Pages: 13

Initiating Coverage with a Neutral Rating and 12-Month Price Target of $26

Provider: DAWSON JAMES SECURITIES, INC.

Price: 50.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 799

08/24/2010

Company Report

Pages: 7

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 800

08/17/2010

Company Report

Pages: 9

Company Acquires Early Stage Drug Candidate for Pompe Disease.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party